A Chinese-developed Covid-19 vaccine candidate triggered a quick immune response in early trials, but the level of antibodies produced was below that of a person recovering from the disease, a study has shown.
The Lancet study examined the results of phase 1 and phase 2 trials in China of the vaccine developed by Sinovac. The group’s vaccine uses a chemically inactivated version of the virus to spark an immune response.
The study found that the level of antibodies 28 days after the last dose of the vaccine was lower than that of a patient recovering from Covid-19.
您已閱讀31%（568字），剩餘69%（1264字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。